Showing 101-110 of 381 results for "".
DermWireTV: Medicare Cuts; Revision, Alastin, Obagi Acquisitions; CSF Hits Nashville
https://practicaldermatology.com/topics/practice-management/dermwiretv-medicare-cuts-revision-alastin-obagi-acquisitions-csf-hits-nashville/20033/Congress is working to avert a potential pay cut for physicians who treat Medicare patients, and a bipartisan solution has been introduced. Cuts loom as the AMA has released data showing that Medicare claims data exclusive to physician services fell an estimated $13.9 billion or 14 percent below expAtopic Dermatitis Journal Club: AD Guidelines May Represent a ‘Paradigm Shift’ in Care
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/atopic-derm-journal-club-ad-guidelines-may-represent-a-paradigm-shift-in-care/24075/In the first video of this series, Derek Chu, MD and Peter Lio, MD talk about new atopic dermatitis (AD) guidelines from the American Academy of Allergy, Asthma and Immunology Joint Task Force. These guidelines potentially represent a reshaping of the approach to AD care and understanding, accordingAsset Protection 101: What Every Dermatologist Should Know
https://practicaldermatology.com/topics/practice-management/asset-protection-101-what-every-dermatologist-should-know/18875/OJM Group principal David Mandell, JD, MBA, reviews the importance of protecting assets for physicians, introduces the asset protection "sliding scale" and outlines basic tools for protecting personal and practice assets.To obtain a free copy of "Wealth Protection Planning for Dermatologists" visitPearls for Treating Atopic Skin
https://practicaldermatology.com/topics/atopic-dermatitis/pearls-for-treating-atopic-skin/29483/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, talks with dermatologist James Del Rosso, DO, about different ways to treat patients with atopic dermatitis (AD), including using a well-made moisturizers, and also exploring both the science and the use of newer topical agents. This- Health Canada Approves Candela's Picoway for Melasmahttps://practicaldermatology.com/news/health-canada-approves-candelas-picoway-for-melasma/2461608/Health Canada has granted Candela’s PicoWay laser system licensing for expanded indications, including the melasma, lentigines, café au lait macules (CALMs), and Nevus of Ota. The US Food and Drug Administration gave the device a similar same nod in Oct
- Allergan Rolls Out New DTC Juvéderm Lips Campaignhttps://practicaldermatology.com/news/allergan-rolls-out-new-dtc-juvederm-lips-campaign/2460281/Allergan is launching its new direct-to-consumer campaign for Juvéderm lips with ads and creative deploying across TV, social media, and digital advertising. As part of the new campaign, New York City-based facial plastic surgeon Dara Liotta, MD, reality television personality Au
- Huma Announces AI Tool to Automate Clinical Notes and Billinghttps://practicaldermatology.com/news/huma-announces-ai-tool-to-automate-clinical-notes-and-billing/2475018/Huma Therapeutics announced the launch Hi Scribe, a generative AI tool for automating clinical documentation and billing, according to a press release from the manufacturer. Huma Therapeutics, a UK- and US-based digital healt
- Huma Announces AI Tool to Automate Clinical Notes and Billinghttps://practicaldermatology.com/news/huma-announces-ai-tool-to-automate-clinical-notes-and-billing/2475019/Huma Therapeutics announced the launch Hi Scribe, a generative AI tool for automating clinical documentation and billing, according to a press release from the manufacturer. Huma Therapeutics, a UK- and US-based digital healt
- Consensus Paper Addresses S. aureus Exacerbated ADhttps://practicaldermatology.com/news/consensus-paper-addresses-s-aureus-exacerbated-ad/2468445/A significant unmet need exists for a single topical atopic dermatitis (AD) therapy effective against all symptoms—including pruritis, S. aureus-driven AD exacerbation, infection, and inflammation—across AD severity levels, according to a panel of six pediatric dermatologists who participated in
- Tralokinumab-ldrm 300 mg/2 mL Single-Dose Autoinjector Available in UShttps://practicaldermatology.com/news/tralokinumab-ldrm-300-mg2-ml-single-dose-autoinjector-available-us/2468195/The Adbry® (tralokinumab-ldrm) 300 mg/2 mL single-dose autoinjector is now available in the United States for patients 12 and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisab